Novartis India's ₹10.89 Cr Tax Dispute Heads to Court

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorAarav Shah|Published at:
Novartis India's ₹10.89 Cr Tax Dispute Heads to Court
Overview

Novartis India Limited is challenging a tax demand of ₹10.89 crore for tax and interest, along with a ₹6.85 crore penalty, from a 2013-14 assessment. The Delhi High Court has now accepted the company's petition, allowing the legal dispute over the ₹17.74 crore sum to proceed.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Novartis India Tax Dispute Moves to Delhi High Court

Novartis India Limited's legal challenge against a significant tax demand has been admitted by the Delhi High Court. The case concerns a tax assessment from the 2013-14 period, with the company contesting a total of ₹17.74 crore.

Court Action

The company announced on March 29, 2026, that it received a court order from the Delhi High Court dated March 27, 2026. This order formally accepts Novartis India's petition to review a tax assessment for the Assessment Year 2013-14. The original tax assessment includes a demand for approximately ₹10.89 crore in tax and interest, coupled with a ₹6.85 crore penalty. The court's admission signifies that the company's plea will now undergo formal legal proceedings.

Why It Matters

By admitting the petition, the Delhi High Court allows Novartis India to formally contest the tax demand and penalty. The total amount at stake, over ₹17.74 crore, is significant. The company has previously stated that it has made provisions for the required pre-deposit amounts in its financial records, which helps mitigate immediate financial pressure related to the case.

Company Context

Novartis India is a prominent player in India's pharmaceutical sector. The company and its related entities have experienced past tax disputes. These include a substantial fine of approximately ₹3 billion (around $49 million) in 2014 from India's National Pharmaceutical Pricing Authority for alleged overcharging. Other tax challenges have also arisen concerning tax deductions and penalties for earlier assessment years.

What's Next

The formal legal process to challenge the tax assessment for AY 2013-14 has now begun. Novartis India will participate in further court proceedings to present its arguments. The company will continue to monitor and report on any developments in the case.

Potential Risks

The core of the dispute reportedly lies in "alleged violations / contraventions" by the company. If the court rules unfavorably, Novartis India could be liable to pay the full demand of ₹10.89 crore (tax and interest) plus the ₹6.85 crore penalty. Additionally, the ongoing legal process may incur further administrative and legal expenses for the company.

What to Watch

Investors and observers will be tracking future court hearings and any new orders from the Delhi High Court. Any interim directives or the final judgment will be key developments. Company disclosures on the progress and outcome of these legal proceedings will also be important to monitor.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.